Subtype
Uterine Neoplasm
CI-CAN-00004208Explore in graph →
Non-malignant925 active trials7 approved drugs44 evidence items
Loading cancer entity…
Subtype
CI-CAN-00004208Explore in graph →
Clinical trials
3,823 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04919629 | APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion | recruiting | Phase 2 | 60 | Roswell Park Cancer InstituteOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT05500391 | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring(SUR-CAN) | recruiting | Phase 2 | 88 | Centre Oscar LambretOTHER | 1 |
| Mar 18, 2026 |
| clinicaltrials |
| NCT07319429 | Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification(FEMUS) | recruiting | Phase 2 / Phase 3 | 260 | Fudan UniversityOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT04712851 | Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia | recruiting | Phase 2 | 25 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05824468 | Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer | active not recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05824481 | Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer | active not recruiting | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04393285 | Abemaciclib and Letrozole to Treat Endometrial Cancer | active not recruiting | Phase 2 | 53 | Gynecologic Oncology GroupNETWORK | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07202364 | A Study of YL202 in Patients With Advanced Solid Tumors | recruiting | Phase 2 | 100 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT00188539 | Cervix: Hypoxia, Interstitial Fluid Pressure and GSH Levels | active not recruiting | Phase 2 | 346 | University Health Network, TorontoOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07453394 | QLS5132 Combination Therapy in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 626 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 6, 2026 | clinicaltrials |
| NCT07450963 | Cadonilimab Combined With RT in LACC Patients Ineligible for CCRT | not yet recruiting | Phase 2 | 45 | Ruijin HospitalOTHER | 0 | Mar 5, 2026 | clinicaltrials |
| NCT06369155 | Azenosertib in Uterine Serous Carcinoma: Biomarker Study | recruiting | Phase 2 | 25 | Joyce Liu, MDOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT03403465 | Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers | active not recruiting | Phase 2 | 90 | Duke UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07435376 | Intra-lesional Tumor Boost for Bulky Cervical Cancer(INTLECTUAL) | recruiting | Phase 2 | 17 | Seoul National University Bundang HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07439497 | Definitive Hypofractionated Intensity-modulated Radiation Theraphy With Concurrent Chemotherapy in Cervical Cancer(DEHIM_CCRT) | recruiting | Phase 2 | 34 | Samsung Medical CenterOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07433283 | Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 54 | Sichuan Enray Pharmaceutical Sciences CompanyOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT05438420 | Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 120 | Qurient Co., Ltd.INDUSTRY | 2 | Feb 24, 2026 | clinicaltrials |
| NCT03624244 | Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)(BFR-ESS) | recruiting | Phase 2 | 40 | Centre Leon BerardOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT04781088 | Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 2 | 38 | Floor Backes, MDOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT03260023 | Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers | active not recruiting | Phase 1 / Phase 2 | 143 | TransgeneINDUSTRY | 3 | Feb 5, 2026 | clinicaltrials |
| NCT06319963 | A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer | recruiting | Phase 1 / Phase 2 | 72 | Theravectys S.A.INDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06710847 | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors(SYLVER) | active not recruiting | Phase 1 / Phase 2 | 14 | GlaxoSmithKlineINDUSTRY | 7 | Feb 2, 2026 | clinicaltrials |
| NCT07371663 | An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 266 | Beijing Tide Pharmaceutical Co., LtdINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07368985 | Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer | not yet recruiting | Phase 2 | 87 | Prof. Dr. Remi A. NoutOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07369986 | Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer(IMMUNE-SAVE) | not yet recruiting | Phase 2 | 30 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 0 | Jan 27, 2026 | clinicaltrials |
| NCT07363330 | A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer | not yet recruiting | Phase 2 | 32 | Zhongnan HospitalOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT04576104 | Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer | active not recruiting | Phase 2 | 51 | Northwestern UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07054567 | A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer | recruiting | Phase 2 | 96 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07348861 | A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer | not yet recruiting | Phase 2 | 25 | Zheng MinOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT03228667 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | active not recruiting | Phase 2 | 40 | ImmunityBio, Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07340489 | Serplulimab for Locally Advanced Cervical Cancer | recruiting | Phase 2 | 216 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06238635 | Dostarlimab and Cobolimab in Advanced Cervical Cancer | active not recruiting | Phase 2 | 66 | Meghan SheaOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT06536517 | The Effects of One-time Intraoperative Methadone During Laparoscopic Hysterectomy in Reducing Opioid Prescription. | recruiting | Phase 2 | 100 | Johns Hopkins UniversityOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06562166 | Online Adaptive Radiotherapy for Cervical Cancer | recruiting | Phase 2 | 124 | Peking Union Medical College HospitalOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05504252 | METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin(METIMMOX-2) | active not recruiting | Phase 2 | 80 | University Hospital, AkershusOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06518564 | Avelumab and M1774 in ARID1A-mutated Endometrial Cancer | recruiting | Phase 2 | 25 | Panagiotis Konstantinopoulos, MD, PhDOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06727617 | Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors | recruiting | Phase 2 | 134 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07080216 | Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer | recruiting | Phase 1 / Phase 2 | 120 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06416696 | Toripalimab for High-risk Locally Advanced Cervical Cancer | active not recruiting | Phase 2 | 57 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04141449 | A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation(Potlako+) | active not recruiting | Phase 2 | 874 | Brigham and Women's HospitalOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT06463028 | Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer | recruiting | Phase 2 | 40 | Faeth TherapeuticsINDUSTRY | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06640283 | Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes(ANA) | recruiting | Phase 2 | 150 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06690775 | CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. | recruiting | Phase 2 | 230 | TORL Biotherapeutics, LLCINDUSTRY | 12 | Dec 23, 2025 | clinicaltrials |
| NCT07298642 | Extended-field Proton Therapy for Cervical Cancer | recruiting | Phase 2 / Phase 3 | 44 | National Taiwan University HospitalOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07108270 | A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC) | recruiting | Phase 2 | 30 | GlaxoSmithKlineINDUSTRY | 1 | Dec 22, 2025 | clinicaltrials |
| NCT07167160 | Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial | recruiting | Phase 2 | 59 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT05106127 | Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem | not yet recruiting | Phase 2 | 28 | Evergreen Therapeutics, Inc.INDUSTRY | 0 | Dec 8, 2025 | clinicaltrials |
| NCT07070518 | Study of GV20-0251 in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 350 | GV20 TherapeuticsINDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07232654 | Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC | recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 1, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 23, 2026source: clinicaltrials